Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback